Mitsubishi Chemical Group Corporation (TYO:4188)
Japan · Delayed Price · Currency is JPY 1,219.00
+34.50 (2.91%)
Aug 7, 2026, 3:30 PM JST
Mitsubishi Chemical Group Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 3,827,582 | 3,703,988 | 4,407,405 | 4,387,218 | 4,634,532 | 3,976,948 |
Revenue Growth | -10.38% | -15.96% | 0.46% | -5.34% | 16.54% | 22.09% |
Gross Profit Gross Profit Growth | 1,142,387 | 1,071,102 | 1,279,594 | 1,146,824 | 1,239,487 | 1,114,724 |
Operating Income Operating Income Growth | 90,375 | 249,943 | 303,207 | 247,501 | 317,793 | 250,894 |
Net Income Net Income Growth | 49,908 | 11,829 | 45,020 | 119,596 | 96,066 | 177,162 |
Earnings Per Share EPS Growth | 36.73 | 8.63 | 31.63 | 80.77 | 64.72 | 115.03 |
EPS Growth | 108.54% | -72.71% | -60.84% | 24.79% | -43.73% | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
MMA & Derivatives MMA & Derivatives Growth | 374,776 | 364,503 | 416,395 | 292,334 | - | - |
Basic Materials & Polymers Basic Materials & Polymers Growth | 840,902 | 821,544 | 1,007,266 | 1,048,459 | - | - |
Others Others Growth | 305,647 | 311,989 | 335,473 | 390,961 | 425,757 | 404,453 |
Unallocated Adjustment Unallocated Adjustment Growth | -223,129 | -228,109 | -211,788 | -262,221 | -308,478 | -309,241 |
Specialty Materials Specialty Materials Growth | 1,122,769 | 1,074,450 | 1,091,614 | 1,225,236 | 1,303,326 | 1,188,838 |
Industrial Gases Industrial Gases Growth | 1,406,617 | 1,359,611 | 1,308,025 | 1,255,081 | 1,186,684 | 957,119 |
Pharma Pharma Growth | - | - | 460,420 | 437,368 | 547,565 | 404,048 |
Total Total Growth | 3,827,582 | 3,703,988 | 4,407,405 | 4,387,218 | 4,634,532 | 3,976,948 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 544,019 | 527,104 | 326,144 | 294,924 | 297,224 | 245,789 |
Total Debt Total Debt Growth | 1,845,053 | 1,890,521 | 2,040,987 | 2,201,011 | 2,243,768 | 2,159,969 |
Net Cash (Debt) Net Cash Growth | -1,301,034 | -1,363,417 | -1,714,843 | -1,906,087 | -1,946,544 | -1,914,180 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -957.60 | -994.83 | -1204.70 | -1285.47 | -1309.12 | -1240.84 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 411,126 | 436,287 | 552,847 | 465,146 | 355,189 | 346,871 |
Capital Expenditures CapEx Growth | -287,655 | -284,089 | -314,533 | -268,686 | -259,026 | -244,851 |
Free Cash Flow Free Cash Flow Growth | 123,471 | 152,198 | 238,314 | 196,460 | 96,163 | 102,020 |
Free Cash Flow Growth | -50.09% | -36.14% | 21.30% | 104.30% | -5.74% | -53.78% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 29.85% | 28.92% | 29.03% | 26.14% | 26.75% | 28.03% |
Operating Margin | 2.36% | 6.75% | 6.88% | 5.64% | 6.86% | 6.31% |
Pretax Margin | 1.63% | 0.02% | 3.42% | 5.48% | 3.62% | 7.30% |
Profit Margin | 1.30% | 0.32% | 1.02% | 2.73% | 2.07% | 4.46% |
FCF Margin | 3.23% | 4.11% | 5.41% | 4.48% | 2.08% | 2.56% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 32.000 | 32.000 | 32.000 | 32.000 | 30.000 | 30.000 |
Dividend Per Share Growth | 0% | 0% | 0% | 6.67% | 0% | 25.00% |
Dividend Yield | 2.70% | 3.56% | 4.50% | 3.76% | 4.25% | 4.26% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 33.19 | 103.25 | 23.30 | 10.90 | 11.63 | 6.55 |
Forward PE | 16.94 | 13.36 | 11.19 | 12.96 | 4.57 | 5.51 |
P/FCF Ratio | 13.41 | 8.03 | 4.40 | 6.63 | 11.62 | 11.38 |
PS Ratio | 0.43 | 0.33 | 0.24 | 0.30 | 0.24 | 0.29 |